Cognition Therapeutics Reports Strong Q2 2025 Results and Advances Alzheimer’s and DLB Drug Development

Cognition’s Progressive Clinical Programs and Financial Results for the Second Quarter of 2025

Announcement

Cognition Therapeutics Inc., a leading clinical-stage company producing advanced drugs for the treatment of neurodegenerative disorders, declared its financial results for the second quarter of the month ending 30th June 2025, and showcased a business update.

Business-oriented Highlights of the Company

The productive EOP2 meeting with FDA reviewed results from the phase to ‘shine’ study of zervimesine (CT1812) for Alzheimer’s disease. The 50% enrollment in the zervimesine phase 2 study for early Alzheimer’s disease, which was held under the partnership with the company Colleagues at the Alzheimer’s Clinical Trials Consortium (ACTC). The positive results from the phase 2 trial and study showed a 28.6% reduced rate of geographic atrophy (GA) lesion, elevated at 18 months, with once-daily oral zervimesine treatment in comparison to placebo. To support EAP, the philanthropic donation, the phase 2 ‘shimmer’ participants, and various DLB patients selected three clinical sites.

The projected results from phase 2 ‘shimmer’ study of zervimesine in DLB were presented on 29th July in Toronto, Canada, at the Alzheimer’s Association International Congress (AAIC). Later submitted to the FDA for drug designation for zervimesine in DLB. The submitted robust manuscript demonstrates a promising mechanism of zervimesine action in the treatment of dry GA/AMD to be added to the peer-reviewed journal or portfolio. The publicly printed proteomics analysis from the phase 2 ‘sequel’ COG0202 study highlighted the impact of zervimesine on major cellular functions in Alzheimer’s disease.

Views and Statements of the Company’s Leaders

President and CEO of Cognition, Lisa Ricciardi, said, “The second quarter of 2025 has been excellently effective with profit from every clinical program. This success or milestone empowers and spotlights our potential for zervimesine to slow down the progression of age-based degenerative diseases like dementia with Lewy bodies (DLB), dry age-based macular degeneration (dry AMD), and Alzheimer’s disease. The clinical findings from every program have been verified by the publication of proteomic analysis and in vitro studies that help the mechanism of action of zervimesine in these patient groups.”

She further added, “Later this month, we asked for the FDA’s minutes from our end-of-phase 2 meeting for registrational plans for zervimesine in Alzheimer’s disease. This will help us move ahead with our understanding of the agency’s expectations for a clinical program in Alzheimer’s disease. We expect the FDA to decide on the breakthrough designation for zervimesine in DLB by the third quarter of 2025. This will be an unforgettable milestone and will be valuable to our partners.”